Celator Pharmaceuticals Inc
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2012 | $39 M | No. 4 | $10 to $50 million | equity, options | SEC | |
| Dec 2011 | $3 M | No. 3 | $2 to $10 million | equity, options | SEC | |
| Aug 2010 | $15 M | No. 2 | $10 to $50 million | equity, options | SEC | |
| May 2010 | $3 M | No. 1 | $2 to $10 million | debt, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Celator Pharmaceuticals Inc had revenue of up to $1 million when it filed its newest notice of a funding round (May 2013).
SEC Form D (revenue range) · May 2013
Revenue range over time, as stated in its notices: revenue between $1 million and $5 million in 2010; revenue between $5 million and $25 million in 2011; revenue of up to $1 million in 2013.
SEC Form D (revenue range) · May 2013
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · May 2013
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Celator Pharmaceuticals Inc is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 306 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Fred M. Powell | Executive officer | May 2013 |
| Jackson T. Scott | Executive officer | May 2013 |
| Lawrence T. Mayer | Executive officer | May 2013 |
| David T. Wood | Executive officer | Aug 2012 |
| David D Wood | Executive officer | Dec 2011 |
| Lawrence D Mayer | Executive officer | Dec 2011 |
| Scott Jackson | Executive officer | Dec 2011 |
| David D. Wood | Executive officer | Sep 2010 |
| Lawrence D. Mayer | Executive officer | Sep 2010 |
| Alex S. Zisson | Director | May 2013 |
| Jackson T. Scott | Director | May 2013 |
| Joseph A. Mollica | Director | May 2013 |
| Kenneth A. Galbraith | Director | May 2013 |
| Nicole S. Vitullo | Director | May 2013 |
| Richard S. Kollender | Director | May 2013 |
| Scott S. Morenstein | Director | May 2013 |
| Alex D Zisson | Director | Dec 2011 |
| Brenda D Gavin, D.V.M. | Director | Dec 2011 |
| Joseph A. Molliica, Ph.D. | Director | Dec 2011 |
| Kenneth Galbraith | Director | Dec 2011 |
| Nicole D Vitullo | Director | Dec 2011 |
| Scott Jackson | Director | Dec 2011 |
| Alex D. Zisson | Director | Sep 2010 |
| Brenda D. Gavin | Director | Sep 2010 |
| J. Kevin Buchi | Director | Sep 2010 |
| Kenneth Kevin Galbraith | Director | Sep 2010 |
| Nicole A. Vitullo | Director | Sep 2010 |
| Lawrence D. Mayer | Director | May 2010 |
| Patrick D. Brady | Director | May 2010 |